Xanthic Biopharma Inc. (CSE:xTHC) (formerly Aurquest Resources Inc.) is pleased to announce that it has signed a binding letter of intent with Green Mile Solutions LLC (“GMS”) to develop plans to manufacture and distribute Xanthic-branded cannabis-infused products in Oregon, Nevada and Ohio. Definitive agreements for each state are expected to be finalized and structured to be fully compliant with local regulatory requirements.

Under these agreements, GMS will facilitate the manufacturing of cannabis-infused powders in licensed facilities utilizing the proprietary Xanthic process to create water soluble THC and CBD.  GMS will procure sales of the finished products into the local licensed dispensary networks through existing sales and distribution channels. Xanthic-branded products are expected to be in production in each market in the second half of 2018.


Tim Moore, CEO of Xanthic, stated: “We are thrilled to have Green Mile Solutions as a strategic partner to expand our footprint in the USA. Its leadership team has tremendous strength and experience in business operations and cannabis production and handling. These three markets represent a significant increase in scale for Xanthic and represents a great addition to our existing arrangements in Colorado.”

Meredith Farrow, CEO of GMS, commented: “Green Mile Solutions is pleased to add the unique product offerings and talent to our overall team that Xanthic brings.”

The Company also announces Adam Mogil has been retained as a consultant to help the company as it moves forward, In lieu of a monthly compensation, Mr. Mogil has been granted 500,000 stock options at an exercise price of $0.40 for twelve months and will expire on April 18, 2019 if not exercised on or before the aforementioned date.

About  Xanthic

Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels. Using a proprietary patent-pending process, Xanthic allows its strategic partners to deliver superior cannabinoid solubility, accurate micro-dosing, increased bioavailability and consistency versus competitive infused products.

Disclaimer:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. There is no assurance that the Company will reach a definitive agreement with GMH and that such agreement will successfully produce benefits for Xanthic. Although such forward-looking statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances, except as required pursuant to applicable securities laws.

SOURCE Xanthic BioPharma

For further information: Tim Moore, CEO, Xanthic Biopharma Inc., timm@xanthicbiopharma.com, Phone: 1-647-966-6536, info@xanthicbiopharma.com

Source: www.newswire.ca

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less